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Abstract
Spaceflight poses unique and significant hazards; the maintenance of human health remains a large 
part of the National Aeronautic and Space Administration (NASA) strategic goals and work remains to be 
done if we wish to maintain a long-term presence in space. The effects of ionizing radiation and bone 
density loss are some of the primary health related problems which need to be addressed. One of the 
main purposes of this research is to translate aspects of thermoregulation and metabolism reduction in 
hibernating species to a non-hibernating species in- order to devise alternative methods of preventing 
DNA damage and loss of bone density in astronauts. A second purpose for this research applies the 
same approach in emergency medicine, having potential as conjunctive therapy for cardiac arrest 
victims. Targeted temperature management (TTM; formerly known as therapeutic hypothermia) is the 
standard of care for these patients and is applied to increase survival rates and reduces neurological 
deficit.
Stimulating Central Nervous System (CNS) A1 adenosine receptors inhibits shivering and non­
shivering thermogenesis, inducing a hibernation-like response in hibernating species. A similar 
phenomenon occurs when using this technique in non-hibernating species such as rats. The adenosine 
A1 agonist, N6-cyclohexyladenosine (CHA) was utilized in all 3 of the experiments to determine how 
dose, diet, ambient temperature, and finally surface temperature affects the thermoregulatory response 
in Sprague-dawley rats. In addition to CHA, the partial agonist capadenoson was also tested for 
thermolytic efficacy (that is, the efficacy to abolish thermogenesis). Surface temperature control using a 
temperature controlled cage designed and built by myself in combination with IV CHA was found to be 
most effective in maintaining a target temperature of 32°C without risk of over-cooling. Results from 
these experiments suggests that the new standard technique in studying TTM using small animals 
should be similar to what is currently used in clinics; surface temperature modulation.
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General introduction
Spaceflight poses unique and significant hazards; the maintenance of human health remains a large part 
of NASA's strategic goals and work remains to be done if we wish to maintain a long-term presence in 
space. The effects of ionizing radiation and bone density loss are some of the primary health related 
problems which need to be addressed (Institute of Medicine (US) Committee on Creating a Vision for 
Space Medicine During Travel Beyond Earth Orbit; Ball JR, 2001). Cardiac arrest is also a significant and 
growing health problem accounting for up to 20% of all deaths worldwide (Hayashi et al., 2015). 
Targeted temperature management (TTM; formerly known as therapeutic hypothermia) is the standard 
of care for out of hospital cardiac arrest patients and reduces mortality and neurological deficits 
(Malhotra et al., 2013; Vargas et al., 2015). Hypothermia may also decrease detrimental effects of 
ionizing radiation (Baird et al., 2011) and improves survival rates of hibernating ground squirrels during 
whole-body radiation exposure (Musacchia and Barr, 1968). Cooling core body temperature, however, is 
complicated by the cold-defense response such as shivering (Badjatia et al., 2008). One of the main 
purposes of this research is to translate aspects of thermoregulation and metabolism reduction in 
hibernating species to a non-hibernating species in- order to devise alternative methods of preventing 
DNA damage and loss of bone density in astronauts. A second purpose for this research is to develop a 
method to inhibit shivering during whole body cooling in emergency medicine.
Chapter 1 of this thesis studies N6-cyclohexyladenosine (CHA) in-order to study the thermolytic and 
metabolic effects of A1 adenosine receptor agonists on rats. In addition to the full agonist CHA, the 
partial agonist capadenoson was also studied. These experiments were done at fixed ambient 
temperatures to determine whether these agonists have potential to lower body temperature for use in 
emergency medicine and possibly during long term human spaceflight to reduce the effects of ionizing 
radiation and bone density loss. Results showed that CHA is so effective that it frequently caused over-
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cooling of the animals. The project then evolved to a third set of experiments using both IV 
administration of CHA and using a cage with the capability of real-time temperature adjustment.
Chapter 2 describes how I designed and built the dynamic temperature controlled cage such that the 
animals would not over-cool when drugs such as CHA are applied to inhibit shivering and other forms of 
thermogenesi. The reasoning for this was to allow for more consistent and/or accurate biological side 
effects of this reduced thermogenesis and implement the three R's known throughout the IACUC 
community: Replacement, Refinement, and reduction animal experiments with the ultimate-goal of 
minimizing pain and distress. In the case of this new apparatus, now called the "dial-a-temp" cage, it 
uses all three of these IACUC axioms. The cage operation is based on dynamic temperature control over 
the cage surface and effectively duplicates what emergency room personnel use to treat cardiac arrest 
victims. The dial-a-temp replaces old techniques such as spraying animals with water-alcohol mixtures 
in-order to utilize evaporative cooling (Zhao et al., 2005; Wang et al., 2012; Liu et al., 2013; Bazley et al., 
2014). It is a refinement of technique that ultimately reduces the total amount of animals used for 
cooling experiments by decreasing error through more precise control of core body temperature. As our 
methods evolved throughout these experiments in the hunt for more accurate temperature control, I 
anticipate our refined approach will be used in future studies of thermolytics, whether they are 
adenosine based or not. Appendix B provides design detail and instructions to construct a dial-a-temp.
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Chapter 1: Optimization of thermolytic response to A i adenosine receptor agonists in rats1
1.1 Abstract
Cardiac arrest is a leading cause of death in the United States and currently, therapeutic hypothermia, 
now called targeted temperature management (TTM), is the only recent treatment modality proven to 
increase survival rates and reduce morbidity for this condition. Shivering and subsequent metabolic 
stress, however, limits application and benefit of TTM. Stimulating central nervous system A 1 adenosine 
receptors inhibits shivering and non-shivering thermogenesis in rats and induces a hibernation-like 
response in hibernating species. Here, we investigated the pharmacodynamics of two A 1AR agonists in 
development as anti-shivering agents. To optimize body temperature (Tb) control we evaluated the 
influence of every-other-day feeding, dose, drug and ambient temperature (Ta) on the Tb lowering 
effects of N6-cyclohexyladenosine (CHA) and the partial A 1AR agonist capadenoson in rats. The highest 
dose of CHA (1.0 mg/kg, IP) caused all ad libitum fed animals tested to reach our target Tb of 32°C, but 
responses varied and some rats over-cooled to a Tb as low as 21°C at 17.0°C Ta. Dietary restriction 
normalized the response to CHA. The partial agonist capadenoson (1.0 or 2.0 mg/kg, IP) produced a 
more consistent response but the highest dose decreased Tb by only 1.6°C.
In order to prevent overcooling with CHA as observed in the previous two experiments, I hypothesized 
that in-floor cooling and warming could obtain our target temperature faster as well as prevent 
overcooling. I designed and built a dynamic surface temperature controlled cage floor that utilizes 
aluminum construction in order to maximize heat transfer and provide an easy to clean surface. After 
testing, we used this approach to study continuous IV administration in combination with dynamic
1 Bailey, I.R.; Laughlin, B.; Moore, L.A.; Bogren, L.K.; Barati, Z.; Drew, K.L.; Journal of Pharmacology and
Experimental Therapeutics; In-Press (JPET Fast Forward)
Published on June 26, 2017 as DOI: 10.1124/jpet.117.241315
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surface temperature control. Results show that after CHA administration control of surface temperature 
maintains desired target Tb better than dose or ambient temperature
1.2 Introduction
Hypothermia is defined as a body temperature colder than 35°C and is a well-known cause of death in 
cold climates. Despite this, the American Heart Association (AHA, 2015; Callaway et al., 2015a) 
guidelines for CPR & Emergency Cardiovascular Care strongly recommends induced hypothermia via 
targeted temperature management (TTM) for treating out-of-hospital cardiac arrest (OHCA), and 
neonatal resuscitation. Clinical trials for TTM in stroke, the leading cause of adult disability (Mozaffarian 
et al., 2015) are ongoing (Lyden et al., 2016). While cooling is neuroprotective, clinical application is 
complicated by side-effects such as shivering.
Paralytics suppress shivering and are used commonly with TTM in comatose patients after cardiac arrest 
(Bernard et al., 2002). With regard to cooling conscious stroke patients, meperidine (IV) in combination 
with buspirone (oral) is currently the treatment of choice to suppress shivering. Synergy between these 
two drugs decreases shivering threshold to a core body temperature (Tb) of 33.5°C with minimal risk of 
respiratory depression,(Logan et al., 2011) (Mokhtarani et al., 2001; Sessler, 2009) however, a shivering 
threshold of 33.5°C is not sufficient for optimal control of shivering at colder Tb. The metabolic stress of 
shivering limits maximum therapeutic benefit of cooling. A recent study(Nielsen et al., 2013) showed no 
difference in outcome in patients cooled to 33°C vs 36°C and questioned the utility of cooling to 33°C. 
Importantly, this study reported shivering at 33°C and 36°C but no differences in adverse effects were 
seen at these temperatures. Other studies confirm shivering at 36°C (Callaway et al., 2015b).
By examining strategies in species which routinely lower Tb, such as hibernators, we sought a safer, 
alternative method of inducing TTM without harmful side effects such as shivering. In Arctic Ground
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Squirrels, stimulation of A 1 adenosine receptors centrally (ICV) or peripherally (IP) using 
N6cyclohexyladenosine (CHA) decreases oxygen consumption (VO2) and leads to a subsequent decrease 
in Tb in a manner that resembles spontaneous onset of hibernation (Jinka et al., 2011). However, for 
unknown reasons, the drug is effective only in the hibernation season. Like the hibernation season in 
AGS, dietary restriction (DR) in rats sensitizes animals to the temperature lowering effects of CHA when 
compared to their ad libitum (AL) fed counterparts (Jinka et al., 2010). Although CHA effectively lowers 
Tb in DR rats, precise control of target temperature has not been achieved in AL rats; and DR is not a 
viable option for human emergency medicine. Currently, it is not known how dose and environmental 
temperature influences final body temperature in AL rats when given CHA, an A 1 selective full agonist 
(van der Wenden et al., 1995) or capadenoson, an A 1 selective partial agonist (Albrecht-Kupper et al., 
2012). The objective of this study was to characterize how dose of CHA, the partial A 1AR agonist 
capadenoson, and environmental temperature influence Tb in freely fed rats for the purpose of precise 
control of Tb between 32-36°C. We measure the rate of oxygen consumption as an indicator of 
thermogenesis, define individual variability in response to capadenoson and to CHA at a dose higher 
than tested previously and show that ambient temperature alone is not sufficient to control the depth 
of cooling. We report that dynamic control of surface temperature in rats, designed to mimic conductive 
cooling used clinically is the most effective means to regulate Tb after CHA.
1.3 Methods
Animals
Experiments were done in accordance with the Guide for the Care and Use of Laboratory animals, 8th 
edition (National Research Council, National Academies Press, 2010) and protocols were approved by 
University of Alaska Fairbanks Institutional Animal Care and Use Committee. Male Sprague-Dawley rats 
(approximately 90 days old) were obtained from Simonson Laboratories (Gilroy, CA) (experiment B) or
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from a University of Alaska Fairbanks colony derived from Simonson Laboratories (experiment A and C). 
All animals were housed in pairs at 21.5-23.0°C on a 12L:12D photoperiod. A summary of experiments 
and number of animals used can be seen (Table 1).
Experiment A: Dietary restriction & ad libitum, 0.5 mg/kg CHA, IP
Prior research had shown that DR increases sensitivity to the Tb lowering effects of 0.5 mg/kg CHA, but 
VO2 was not measured as an indication of thermogenesis. Here we asked if CHA suppresses VO2 prior to 
the decrease in Tb, consistent with suppression of thermogenesis, and test the influence of 36 days of 
every-other-day feeding on the thermolytic response to CHA.
Temperature data loggers (iButton; Maxim Integrated, Sunnyvale, CA) were coated with wax and 
surgically implanted into the abdominal cavity and programmed to record temperature every 10 
minutes. After a 10-14 day post-operative recovery period rats were either fed every other day (DR) or 
AL up to 40 days. Feeding or food removal was done at 10-11AM every day. Body weights were 
measured every four days. Between 36-40 days after starting the DR protocol animals were moved to a 
clean cage and housed individually at an ambient temperature of 16.2 ± 0.5°C (mean ± SD) for 24h prior 
to treatment. Rats were moved to a metabolic chamber for 3 h prior to treatment with CHA (0.5 mg/kg, 
IP) or Vehicle (1.0ml/kg, IP) and remained in the metabolic chamber for 2h post-injection. VO 2 was 
measured by open flow respirometry as detailed below.
Experiment B: Ad lib feeding, 1.0 mg/kg CHA, 1.0 and 2.0 mg/kg capadenoson
We next investigated the effects of 1.0 mg/kg CHA and 1.0 and 2.0 mg/kg of the partial A 1AR agonist 
capadenoson in AL fed rats. Rats were instrumented with iButton data loggers as described for 
Experiment A. All animals, housed in pairs, were placed at an ambient temperature of 17.0±0.5°C (mean 
± SD) 24h before injections and remained at this ambient temperature until 24h after injection. Each of
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the 5 pairs of animals received a different treatment per week based on a balanced cross-over design 
(Table A1). All treatments were given via IP injections and consisted of CHA (1.0 mg/kg), CHA Vehicle 
(1.0 mL/kg), capadenoson (1.0 and 2.0 mg/kg), and capadenoson vehicle (1.0 mL/kg). Heart rate was 
monitored with a digital stethoscope (Littmann© Model 4000 electronic stethoscope; 3M, St. Paul, MN).
Experiment C: Ad lib feeding, IV CHA @ 0.25 mg/kg/h with surface temperature modulation
Finally, we applied dynamic control of surface temperature to optimize control over Tb with CHA 
administered by continuous IV infusion. A temperature controlled cage was built to modulate Tb in 
animals treated with CHA. Two male rats were implanted with telemetry transmitters (CTA-F40; Data 
Sciences International, New Brighton, MN) inside the abdominal cavity and ECG leads were secured to 
the chest wall. The femoral artery was cannuated using 12cm 3Fr C30PU-RECA1302 polyurethane 
catheters (Instech, Plymouth Meeting, PA). The femoral vein was also cannulated using C30PU-RJV1420 
catheters; both cannula were passed through an inter-scapular incision where they were attached to a 2 
channel vascular harness (VAD115AB; Instech). For post-operative recovery animals were housed 
individually with cotton pads substituted for wood shavings. Sutures were removed 7-10 days post op 
and catheter maintenance was done by flushing every 5 days using saline followed by filling with a 
locking solution of heparin/glycerol (500 IU/mL, 50:50) to prevent clotting. On the day of the 
experiment, animals were placed on the cage surface with the initial surface temperature set to 17°C. 
CHA was administered by continuous IV infusion (0.25 mg/kg/h). When animals approached a target Tb 
of 32°C, surface temperature was increased to 32°C to maintain target temperature.
Drugs
CHA (CAS 36396-99-3) is eliminated with a half-life of approximately 2 hours when given subcutaneously 
(Tuovinen and Tarhanen, 2004) and is a full A 1AR agonist (van der Wenden et al., 1995). CHA (Sigma-
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Aldrich; St. Louis, MO) was dissolved in 25% (w/v) hydroxypropyl-p-cyclodextrin (CD) (TCI America, 
Portland, OR) then diluted to 2.5% in physiological saline. CHA vehicle consisted of 25% (w/v) 
hydroxypropyl-p-cyclodextrin diluted to 2.5% in physiological saline. Capadenoson (CAS 544417-40-5) is 
a partial A1AR agonist relative to CCPA (6-chloro-N6-cyclopentyladenosine) and shows a half-life of 
approximately 20 hours (Albrecht-Kupper et al., 2012). Capadenoson (>98% purity; Chemexpress, 
Monmouth Junction, NJ) was dissolved in 100% polyethylene glycol (PEG400; Med Lab Supply, Pompano 
Beach, FL) then diluted to 60% PEG concentration with sterile water. All substances were USP grade 
where available. Solutions for injection were sterilized by 0.2^m filtration (Acrodisc syringe filter; Pall 
corp., Port Washington, NY).
Oxygen consumption (VO2)
VO2 was measured using open-flow respirometry in conjunction with LabGraph respirometry acquisition 
and analysis software according to (Toien, 2013) and (Jinka et al., 2011). The accuracy and integrity of 
the system was calibrated by burning ethanol (100%) following established methodology (Toien, 2013); 
analyzers were manually calibrated with atmospheric reference air (~0.03% CO2 ), zero air (~0% CO2 ), and 
span gas (~0.51% CO2) before each group of experiments and auto-calibrated subsequently every two 
hours. VO2 data was synchronized with Tb by subtracting a lag time of 4 min calculated as the volume of 
the chamber and length of the outlet tube.
Statistical Analysis
Variation in Tb , body mass, and VO2 was analyzed using repeated measures linear mixed-effect models 
(Domidenko, 2004) to account for within-rat correlations and to model time trajectories after treatment 
or feeding regimen. These statistical analyses were conducted using the IBM SPSS Statistics 19. Post-hoc 
comparisons were performed using t-tests with Bonferonni corrections (Excel 2007). The significance 
criterion was a  < 0.05 for all analyses. Data are shown as mean ± SEM unless otherwise indicated.
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1.4 Results
Dietary restriction; 0.5 mg/kg IP CHA
We investigated the influence of every other day feeding on whole animal oxygen consumption and on 
the circadian rhythm in Tb to assess the influence of dietary restriction on thermoregulation. DR 
decreased Tb compared to animals fed AL (diet x time (F(1,13.10) = 7.95, p = 0.014) and main effect of 
diet (F(1,12.37) = 8.97, p = 0.011)). Post hoc tests show that the Tb in DR animals in comparison to AL 
were statistically different on days 4-36, except for days 5, 7 and 17 (p<0.05) as shown in Figure 1.1A. 
Next, we asked whether DR affected Tb across the circadian rhythm or only during the light or dark 
phase of the cycle. Analysis of Tb on the day prior to CHA administration (a feeding day; Figure 1.1B) 
shows that DR decreases the amplitude during the dark, active period [main effect of time (F(1,343) = 
5.15, p = 0.024) and diet (F(1,43.51) = 7.74, p = 0.008) with a near-significant interaction between diet 
and time (F(1,343) = 3.48, p = 0.063). Assessment of the rhythm in Tb during the lights on (inactive) 
period was confounded by disturbance associated with feeding and cage cleaning. DR also decreased 
weight gain relative to AL animals (Figure 1.1C; diet x time (F(1,13.50)=6.28, p=0.026)).
We next assessed the effects of CHA on Tb or VO 2 in DR and AL fed rats. Rats in both DR and AL groups 
maintained Tb at approximately 37.5°C when given vehicle (Figure 1.2A). Both groups responded to 0.5 
mg/kg IP CHA but the DR group showed a larger, more consistent response than the AL group (n=4 AL, 
n=4 DR). Within 120 minutes of injection, Tb in the AL group reached 35.1±1.2°C and Tb in the DR group 
reached 32.5±0.1°C (diet x time x treatment (F(3,140.04) = 18.19, p < 0.001) with a significant main 
effect of time (F(1,140.04) = 59.86, p < 0.001). Post-hoc t-tests showed that the CHA group was 
significantly different than vehicle in DR animals (p<0.05) at 40-120 min after injection. The Tb in the AL 
group after CHA was not different from vehicle (p>0.05). We observed a bimodal distribution in the 4 AL
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fed rats after giving 0.5mg/kg CHA ; two rats maintained Tb similar to vehicle while the other two 
showed a decrease in Tb similar to DR rats given CHA [Figure A1].
In order to see if CHA decreased Tb as a result of an inhibition of thermogenesis, we measured VO2 as an 
indirect measure of both shivering and non-shivering thermogenesis in both DR an AL rats. Compared to 
rats given vehicle, VO2 tended to decrease in both AL and DR rats within 10 min after CHA injection 
(Figure 1.3A). VO2 stabilized at minimal levels within 30 to 50 min after CHA administration and tended 
to be lowest in the DR group. Pair-wise comparisons revealed significant differences between CHA 
treated and Vehicle treated DR rats at 40-120 minutes (p<0.05) and also between AL CHA and vehicle 
treated rats between 70-120 minutes (p<0.05). IP injections with CHA or vehicle tended to produce an 
immediate increase in VO2 except where rats decreased Tb after CHA (Figure 1.3B and Figure A2). In 
these animals VO2 decreased before Tb and is consistent with a decrease in thermogenesis.
Ad lib feeding -1 .0  mg/kg IP CHA, 1.0 & 2.0 mg/kg Capadenoson & Vehicles
We tested a higher dose of CHA (1.0 mg/kg) and two doses (1.0 and 2.0 mg/kg) of the partial agonist 
capadenson to test the hypothesis that a maximally effective dose or alternative A 1AR agonist would 
decrease variation in cooling with AL animals. In addition, to assess if the circadian rhythm of Tb 
influenced drug response we graphed Tb for 3 days prior to drug administration. The circadian rhythm of 
body temperature was noted visually, but not analyzed further (Figure 1.4). Both doses of capadenoson 
cooled Tb to a minimum within 2h of injection. Minimum Tb (mean ± SEM) was 37.0 ± 0.2, and 36.6 ± 
0.2°C for 1.0 mg/kg, and 2.0 mg/kg respectively (Figure 1.4). Analysis of the minimum core Tb yielded a 
significant main effect of treatment (capadenoson 1.0 or 2.0 mg/kg, or vehicle) (F(2,18) = 17.52, p < 
0.001). Pair-wise comparisons of minimum Tb revealed a significant difference between 1.0 mg/kg 
capadenoson and vehicle (p = 0.008) and 2.0 mg/kg capadenoson and vehicle (p < 0.001) and trended 
towards significance between 1.0 mg/kg and 2.0 mg/kg injections (p = 0.081). Capadenoson lowered
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heart rate with a minimum of 77.1% of vehicle baseline for the 1mg/kg dose and 71% for the 2mg/kg 
dose within 2h post injection [Figure A3].
While a dose of 0.5 mg/kg of CHA in AL animals resulted in Tb decreases in two out of four animals, the 
higher dose of CHA (1.0 mg/kg) produced a notable decline in Tb in all animals (10/10). Nonetheless, the 
magnitude and duration of response still varied between animals (Figure 1.4). The lowest minimum Tb 
recorded was 20.6°C while the highest minimum Tb was 32.5°C. We asked whether this variation was 
intrinsic to each animal by giving CHA (1.0 mg/kg) to all animals a second time with one to five weeks 
separating the two injections. In seven out of ten animals the decline in Tb after the second injection 
mirrored closely the response to the first injection (Figure 1.5a); however in three animals it did not. 
Statistical analysis on the minimum core Tb within 20.5h after injection showed that CHA produced a 
significant decrease in Tb on both injections (treatment (first injection, second injection, or vehicle): 
F(2,18) = 36.57, p < 0.001) with significant differences between CHA first injection and vehicle (p < 0.001, 
t-test) and CHA second injection and vehicle (p < 0.001, t-test )). Moreover, there was no significant 
difference between the first and second injection of CHA (p = 1.000, paired t-test). Regression analysis 
of minimum Tb on the first and second injections yielded an R2 value of just 0.43, (p=0.043) [Figure A4]. 
Body weight on the day of injection did not predict the magnitude of the cooling response (p=0.72, first 
injection; p=0.25, second injection). Moreover, neither time nor change in body weight between 
injections predicted response on the second injection (p=0.82) [Table A2]. In addition to lowering Tb, 
CHA caused a 74.5% reduction of heart rate in comparison to vehicle on average within 2h of injection 
[Figure A3]. Bradycardia resolved between 24-48h after injection [Figure A5].
Ad lib feeding - 0.25 mg/kg/h IV CHA @ 2y.l/min
We next asked if surface cooling would normalize Tb and prevent over cooling. We designed and built a 
temperature controlled cage to model surface cooling used clinically and adjusted surface temperature
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to prevent over cooling. During continuous IV infusion of CHA (0.25 mg/kg/h) in the absence of a bolus 
loading dose, animal Tb approached 32°C within 3 hours on a surface temperature of 17°C. Increasing 
surface temperature to 32°C maintained target temperature and prevented overcooling (Figure 1.6). 
Heart rate declined rapidly at the start of CHA infusion and bradycardia persisted throughout the 
infusion (Figure 1.6).
1.5 Discussion
Thermolytics include antipyretic drugs such as acetaminophen and certain non-steroidal anti­
inflammatory drugs (Section on Clinical et al., 2011). Here, we extend the definition of thermolytic to 
include drugs that suppress thermogenesis and decrease core Tb. Despite the ability of CHA to suppress 
thermogenesis precise control of Tb around a predetermined target temperature had yet to be 
demonstrated prior to this work. Our objectives were to define how dose of CHA and environmental 
temperature influence Tb in rats treated with CHA. IP Bolus injections using CHA at 0.5 and 1.0 mg/kg 
failed to produce consistent decreases in Tb, however, use of the higher dose decreased Tb in all animals 
down to or below our target temperature of 32°C at an ambient temperature of 17°C. From this, we 
hypothesized that overcooling could be prevented with cage surface temperature modulation and thus 
facilitate management of target Tb. Here, we report precise control of Tb using CHA coupled with 
dynamic control of cage surface temperature and show that modulation of dose alone is not sufficient 
to precisely manage target Tb.
Our results demonstrate robust thermolytic efficacy of CHA in rats and is a refinement of prior attempts 
with high doses of purine derivatives. AMP was the first purine reported to induce a torpor-like state in 
rats (Zhang et al., 2006) and both AMP and ATP were later tested in rats to lower Tb for therapeutic 
benefit (Zhang et al., 2009; Zhang et al., 2013). High doses were necessary in order to promote sufficient 
cooling, ultimately producing unwanted effects which discouraged further development. AMP induced a
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hypothermic response in mice (Swoap et al., 2007) and was later found to act as an A 1AR agonist; (Muzzi 
et al., 2013) AMP-induced cooling was blocked using an A 1AR antagonist in the CNS (Iliff and Swoap,
2012). Targeting CNS A 1AR using CHA to inhibit thermogenesis shows promise as an effective approach 
to relieve shivering during therapeutic hypothermia (Jinka et al., 2015).
Other non-purine based thermolytics currently in development include neurotensin receptor agonists 
(Choi et al., 2012; Wei et al., 2013), transient receptor potential (TRP) agonists and antagonists (Almeida 
et al., 2012; Feketa et al., 2014; Feketa and Marrelli, 2015), GABAa  agonists (Cerri et al., 2013), and other 
unique formulations (Katz et al., 2012a; Katz et al., 2012b; Katz et al., 2015). Using a fixed ambient 
temperature, several studies demonstrate control of target temperature through modulation of dose 
and dosing regimens alone to maintain Tb or prevent overcooling, (Muzzi et al., 2013; Wei et al., 2013; 
Feketa et al., 2014) however thermolytic efficacy of other drugs tested to date in rats has not been as 
great as CHA.
Few preclinical studies combine dynamic temperature control with thermolytics in search for optimal 
temperature management protocols (Almeida et al., 2012) (Katz et al., 2012b) (Cerri et al., 2013). In the 
clinic, induction methods vary, but may include packing ice into axillary and groin areas and infusing ice- 
cold IV saline. Once target temperature is reached Tb is usually maintained with water-blanket surface 
cooling (Luscombe and Andrzejowski, 2006) (Blanketrol or Arctic Sun, etc) or endovascular cooling. 
Surface temperature control devices are routinely used in clinical settings and are standard protocol at 
most hospitals (Callaway et al., 2015a).
Although we found here that surface temperature modulation prevented overcooling, our data does not 
explain the large individual variation in Tb response to CHA. This variation was unexpected since prior 
work suggested more consistent responses between animals (Jinka et al., 2010), (Jinka et al., 2015). We 
did not observe significant variation using the same animals with the partial agonist capadenoson, but
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consistency came at the cost of thermolytic efficacy.
Current knowledge suggests A 1AR agonist-induced cooling is due to an inhibition of thermogenesis at a 
central site of action(Anderson et al., 1994; Tupone et al., 2013). However, peripheral mechanisms such 
as the inhibition of lipolysis could also impair nonshivering thermogenesis in brown adipose tissue 
(Asakura, 2004; Viswanadha and Londos, 2006). It is unclear whether these mechanisms are responsible 
for individual differences in Tb lowering effects of CHA, but our results reflect what might be expected in 
a diverse clinical population.
Similar variation in response to CHA is seen in ground squirrels where sensitivity to CHA depends on the 
hibernation season. In Arctic Ground Squirrels (AGS), stimulation of CNS AiARs with CHA induces a 
torpor-like state, but the drug is effective only in the hibernation season (Jinka et al., 2011). Seasonal 
sensitivity to CHA in AGS precedes a decrease in food intake and is predicted by a gradual decrease in Tb 
as animals approach the hibernation season (Olson et al., 2013) (Sheriff et al., 2012). In rats, prolonged 
every-other-day feeding increases sensitivity to the temperature lowering effects of CHA as well as 
surface expression of A 1AR in hypothalamus (Jinka et al., 2010). While increases in surface expression of 
A 1AR may contribute to increased sensitivity, prolonged restriction of diet is not a viable approach to 
normalize response to A 1AR agonists in emergency medicine.
Shivering is one of the most problematic issues in TTM which can impede induction of hypothermia by 
doubling metabolic rate (Badjatia et al., 2008), which leads to a stress-like response . Despite the 
importance of metabolism reduction, one of the primary desired effects in administering TTM, limited 
O2 consumption data has been reported for other thermolytics in development. Recently however, it 
was revealed that O2 consumption was reduced using TRPv3 agonists to induce hypothermia in mice, 
but these results could not be replicated in rats (Feketa and Marrelli, 2015). Here, evidence supporting 
inhibition of thermogenesis comes from a decrease in the rate of oxygen consumption (VO2) that
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precedes a decrease in Tb. A similar hysteresis of VO2 and Tb decline is seen during the onset of 
hibernation and torpor (Jinka et al., 2011).
Generalization of the current results in rats to other non-hibernating species such as swine and humans 
is likely because rats do not hibernate naturally. By contrast, many strains of laboratory mice 
spontaneously enter shallow torpor in response to fasting (Geiser, 2004). Results from studies using 
mice may not translate to species that do not hibernate, as evident in the study of TRPv3 agonists 
(Feketa and Marrelli, 2015). For this reason mice are less preferred in the investigation of thermolytic 
efficacy in comparison to rats or swine.
One limitation of this study, and others using small animals to study whole-body cooling is that surface 
area to weight ratio is far smaller than in larger animals including humans. An important next step in 
evaluating thermolytic efficacy is to utilize larger animals. In the present study the rate of cooling was 
faster following IP injection than with continuous IV administration because a loading dose was not 
given prior to IV infusion. Another limitation not addressed here is the potentially detrimental effects of 
adenosine receptor-induced bradycardia and hypotension, a side effect of CHA and hypothermia.(Nieri 
et al., 2001) We have found previously that co-administration of the peripherally acting adenosine 
receptor antagonist, 8-sulfophenyltheophylline (8-SPT), reverses bradycardia and improves survival and 
neurologic outcome after cardiac arrest in rats (Jinka et al., 2015) without interfering with the 
thermolytic effect of the drug. Work is in progress to characterize the effects of 8-SPT on hypotension 
during CHA assisted cooling.
A recent trial (Nielsen et al., 2013) showed no difference in outcome in patients cooled to 33°C vs. 36°C 
and questioned the utility of cooling to 33°C. By contrast, an exhaustive number (over 50) of preclinical 
studies demonstrate that deeper cooling is better (Lyden et al., 2006; Polderman, 2009). Moreover, 
Nielsen noted shivering at 33°C and 36°C and no differences were found in other adverse effects of 33°C
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vs. 36°C; other studies confirm shivering at 36°C (Callaway et al., 2015b). Importantly, the benefit to risk 
of colder Tb may increase as severity of brain injury increases (Yenari and Han, 2012). In response to the 
Nielsen paper the original International Liaison Committee on Resuscitation (ILCOR) recommendations 
indicating 32-34°C(Donnino et al., 2015) has been changed to recommend a target Tb between 32°C and 
36°C.(Donnino et al., 2015). The current study is the first report to our knowledge of the effects of 
capadenoson on body temperature. Capadenoson is a partial agonist that produces 75% of full agonist, 
CCPA (2-chloro-N6-cyclopentyladenosine), [35S]GTPyS binding in human cortical membranes. In 
Langendorff heart preparations capadenoson reduces heart rate to a maximal of 10% of the bradycardia 
produced by the full agonist CCPA. At higher doses CCPA produces complete AV block.(Albrecht-Kupper 
et al., 2012) The limited bradycardia with capadenoson reported by others is consistent with results 
reported here. Given the absence of cardiovascular risk the mild hypothermic effect of capadenoson 
may be useful when a target Tb of 36°C is desired.
In summary, we show pronounced thermolytic efficacy of CHA with unexplained variation that is 
resolved under dietary restriction, but is not resolved with dose in ad libitum fed animals. Although high 
thermolytic efficacy produced over-cooling in some animals, dynamic control of surface temperature 
allowed for fine tuning and maintenance of a prescribed target Tb. This approach to reduce and maintain 
target Tb in rodents is a refinement over fixed ambient temperatures or evaporative cooling protocols 
where animals are sprayed with water or alcohol to facilitate heat loss (Klahr et al., 2017), and mimics 
surface cooling used in the clinic. This new thermolytic class of drugs has potential to facilitate targeted 
temperature management by inhibiting thermogenesis, providing new avenues for treatment.
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Table 1. Summary of experiments
Experiment Experimental
test
Drug Doses Route Ambient
temperature
Sample size
1 Diet and 
Oxygen 
Consumption
CHA 0.5 mg/kg IP - bolus 16°C 15
2 ^  Dose of 
CHA
CHA 1.0 mg/kg IP - bolus 17°C 10
Compare
Partial
Agonist
Capadenoson 1.0 and
2.0 mg/kg
IP - bolus 17°C 10
3 Surface 
temperature 
modulation 
with IV CHA
CHA 0.25
mg/kg/h
IV - 
continuous
16°C - 32°C 2
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Figure 1.1: The effects of every other day feeding (dietary restriction; DR) on body temperature and 
weight gain over 36 days
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Figure 1.1 (continued):
(A) Every other day feeding (dietary restriction; DR) decreases body temperature (Tb) relative to ad 
libitum (AL) feeding.(B) The decrease in body temperature is greatest during the active period. 
Light:dark cycle is indicated by colored bar below. (C) The effects of dietary restriction did not maintain 
the same rate of weight gain in comparison to rats fed ad libitum. Ta is 20°C, mean ± SEM, n=7 AL; n=8 
DR, * p<0.05, ** p<0.01, *** p<0.001 DR vs. AL.
Figure 1.2: The effects of 0.5mg/kg N6-cyclohexyladenosine (CHA) on body temperature in dietary 
restricted and ad-libitum fed rats
Treating rats with the A 1AR agonist 6N cyclohexyladenosine (CHA) at an ambient temperature of 16°C 
decreases Tb. The decrease in Tb is greater in DR rats than in AL rats. Ta is 16°, mean ± SEM n=4 (DR CHA), 
n=4 DR VEH, n=4 (AL CHA), n=3 (AL VEH). Error bars not shown are smaller than symbols. * p<0.05, ** 
p<0.01, *** p<0.001; DR CHA vs. DR vehicle.
28
Figure 1.3: The effects of 0.5mg/kg CHA on body temperature vs. oxygen consumption in dietary 
restricted and ad-libitum fed rats
(A) Dietary restriction significantly lowered oxygen consumption (VO2 ) for both vehicle and CHA treated 
rats (B) Simultaneous measurements of Tb and VO2 in the DR group shows that VO2 declines prior to Tb. 
Ta is 16°C, (mean ± SEM, n=4 (DR CHA), n=4 DR VEH, n=4 (AL CHA), n=3 (AL VEH).
29
Figure 1.4: The effects of 1.0mg/kg CHA and capadenoson on body temperature in rats
CHA (1.0 mg/kg) is more effective than either dose of capadenoson (1.0 and 2.0 mg/kg) at reducing body 
temperature. Variation in both magnitude and duration of response to CHA was not decreased by the 
higher dose (indicated by SEM; lighter shaded area). Arrowheads indicate time when rats were picked 
up for heart rate measurements.
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Figure 1.5: Individual animal variation when given two injections of 1.0mg/kg CHA
Response to CHA (1.0 mg/kg) on the first injection (red lines) did not predict the response on the second 
injection (blue lines) in three out of ten rats. Colored region indicates ambient temperature (red, 23°C; 
blue, 17°C).
31
Figure 1.6: Surface temperature controls body temperature using CHA in rats
To prevent animals from over cooling with CHA on board, cage surface temperature was heated or 
cooled as needed. The cage floor was set to 17oC initially (blue region) and brought up to 32oC (red 
region) as body temperature reached the target temperature of 32oC to prevent overcooling. At this 
dose of CHA, heart rate drops to about 20% of baseline and is followed by a decrease in body 
temperature. This temporal relationship between body temperature and heart rate is similar to what is 
seen at onset of hibernation and is consistent with CHA-induced inhibition of thermogenesis. Ambient 
temperature within the cage did not vary significantly.
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Appendix: Supplemental figures for chapter 1
Figure A1: Ad libitum fed rats given 0.5mg/kg CHA diverge into low responders and high responders 
In AL animals, CHA (0.5 mg/kg) produced a bimodal response.
Low responding animals resembled vehicle treated animals, and high responding animals resembled 
DR fed animals. Ta is 16°C, mean, n=2 AL CHA low responders; n=2 AL CHA high responders; 
n=3 AL, Vehicle.
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Figure A2: Ad Libitum fed rats responding to 0.5mg/kg CHA show a lower oxygen consumption rate in 
comparison to the low responding animals.
Oxygen consumption declines sharply after 0.5 mg/kg CHA in DR animals (n=6). After AL feeding, 
animals that showed a large response to CHA (n=2) decreased V O 2 at a rate similar to the decline in Tb. 
By contrast, animals that showed a low response to CHA displayed an abrupt increase and then 
decrease in VO 2 with no change in Tb. Ta is 16°C, mean, n=4 (DR) , n=4 (AL).
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Figure A3: Bradycardia response to CHA and capadenoson injection in rats.
CHA and capadenoson-induced cooling is associated with bradycardia. The magnitude of bradycardia is 
greatest after CHA. Ta is 17°C, n=10.
Figure A4: Correlation for animals given two injections of N6-cyclohexyladenosine.
Minimum Tb after the first injection of CHA predicted weakly minimum Tb after the second injection of 
CHA with an R2 of 0.43 (p=0.041), n=10.
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Figure A5: Heart rate follows N6-cyclohexyladenosine induced body temperature reduction. 
CHA-induced bradycardia tended to precede the decline in Tb. Ta is 16°C, mean, n=10.
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Table A1. Balanced block design for experiment 2
Group Week 1 Week 2 Week 3 Week 4 Week 5
1
(n=2)
CHA Vehicle Cap
Vehicle
CHA
1mg/kg
Cap 1mg/kg Cap 2mg/kg
2
(n=2)
Cap 2mg/kg CHA Vehicle Cap Vehicle CHA 1mg/kg Cap 1mg/kg
3
(n=2)
Cap 1mg/kg Cap 2mg/kg CHA Vehicle Cap Vehicle CHA 1mg/kg
4
(n=2)
CHA 1mg/kg Cap 1mg/kg Cap 2mg/kg CHA Vehicle Cap Vehicle
5
(n=2)
Cap
Vehicle
CHA 1mg/kg Cap 1mg/kg Cap 2mg/kg CHA Vehicle
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Table A2. Minimum T b , body weight and time between CHA injections
1st Injection 2nd Injection Time between
Rat ID Body wt (g) Min Tb (°C) Body wt (g) Min Tb (°C) injection (weeks)
282 402 32.059 408 32.059 3
283 402 20.635 430 22.136 3
284 405 26.113 400 28.612 2
285 404 29.153 412 29.153 2
286 407 24.563 382 21.562 1
287 476 32.103 470 31.104 1
288 380 36.107 432 28.613 5
289 397 24.649 430 27.648 5
290 376 25.107 415 26.107 4
291 400 22.097 453 28.597 4
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Chapter 2: A dynamic temperature metabolic cage for studying hypothermia in small animals2 
2.1 Abstract:
The prior standard in studying therapeutic hypothermia methods in small animals has been done by 
spraying animals with water or a mixture of water and alcohol in-order to use the high latent heat of 
vaporization for cooling purposes (Zhao et al., 2005; Wang et al., 2012; Liu et al., 2013; Bazley et al., 
2014). In refinement of this technique, we hypothesized that surface temperature control would achieve 
much better control over body temperature and minimize adverse reactions to the water & alcohol 
mixtures. This new cage operates in a similar fashion to in-floor heating that is commonly implemented 
in residential housing. A key difference here is that the floor can be either heated up or cooled down 
between 4°C and 36°C quickly and is limited to the temperatures for animal comfort when working with 
Sprague-Dawley rats. The cage could theoretically be cooled to approximately -20°C or warmed past 
40°C in the present configuration with limitations coming from the supporting refrigerator cooling 
power. Here we describe a method of cage construction and provide results that define specifications 
regarding surface temperature control.
2.2 Methods:
Overview
The primary method of temperature adjustment is done by using the peltier effect to move heat to or 
from the cage surface and into a heat exchanger located inside the supporting refrigerator. The 
refrigerator is not needed if desired cage temperature is between approximately 14°C and 37°C; in this 
case a radiator and fan will reject waste energy from the system. For cooler target temperatures the
2 Bailey, I.R., "Methods of temperature & metabolism reduction in rats and possible influence on human 
health" (M.S. thesis, University of Alaska Fairbanks, 2017), 39-53
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radiator, fan, power supply, and water pumps are housed inside the refrigerator to eliminate waste heat 
and minimize equipment noise levels. A diagram of the dial-a-temp general configuration for 
hypothermia studies in small animals can be seen in figure 2.1.
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Cage floor
For construction of the cage floor, a pair of 12"x12"x0.125" 6061 T6 aluminum plates were welded to 
four sides constructed of 12"x1"x0.125" aluminum flat stock. A strip of 8"x0.75"x0.125" was placed 
medially to channel water evenly throughout the interior space. Water inlet and outlet fittings were 
made out of 0.75"x0.125" round tube and welded directly to the side of the cage and then two holes 
were drilled and de-burred for smooth water passage. All cage construction materials are of the 6061 T6 
alloy and was chosen due to a very high Brinell hardness of weldable aluminum alloys. Welding prior to 
drilling and tapping afforded extra surface area for sealing the threads of a 1/4" NPT male Schrader 
valve which was used to burp air out of the system before normal operation. During operation, 
insulation is recommended underneath the cage and will reduce losses due to heat transfer in addition 
to more accurate temperature sensor input.
Cage top
The cage top was fabricated using five 11"x11"x0.125" thick polycarbonate (plexiglass) sheets with one 
reserved for the cage lid. A 12"x12"x0.125 sheet was solvent-welded to one of the 11"x11"x0.125" 
sheets in the center to provide an interference-type fit so that most of the incoming air is limited to the 
central hole when using respirometry equipment to draw air in. Air and respiratory gasses then exit the 
cage through four fittings tapped at animal height. These fittings are placed such that any stagnant air 
respired by animals is captured in addition to a faster cage wash-out. In place of the polycarbonate lid, 
1/8" stainless TIG filler wire can be cut and welded together into a wire cage-top to promote open air 
exchange if respirometry equipment is not used. The polycarbonate lid should NOT be used if 
respirometry equipment is not continuously pulling in fresh air in as the animal may asphyxiate due to 
inadequate air flow.
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Heat transfer plates
The two identical heat transfer blocks are constructed of 1"x3"x0.125" by approximately 10" long 6061 
T6 rectangle tube with 1"x0.125" flat stock welded on both ends as end caps. Each end cap received a 1" 
long 0.75"x0.125" round tube for water in and out fittings; after welding the interior was drilled and de­
burred. These two blocks are used in conjunction with four potted Peltier modules and are clamped 
together forming the heat transfer block.
Methods o f temperature control
Design V1.1 included a home-made H-bridge array of relays controlled digitally by aftermarket 
refrigerator controllers, commonly used in kegerator setups. In-order to eliminate failures of mechanical 
relays used in the previous design, a stand-alone control unit was obtained (TC-720; TE Technology Inc., 
Traverse City, MI) that uses semi-conductor switching in the form of transistors, increasing reliability. 
The control module also uses PWM (pulse width modulation) to drive the Peltier modules in order to 
minimize heat cycling of the internal semi-conductors, further increasing reliability.
The TC-720 uses one primary thermistor to use in the PID (Proportional, Integral, Derivative) algorithm 
and a secondary thermistor to obtain ambient temperature. This secondary sensor could also be used to 
monitor equipment temperature or other experimental parameters.
The only drawback to using this control unit over an H-bridge relay setup is a 20 amp nominal current 
limitation. Based on a year of operation, short bursts of up to 25 amps seems to be tolerated by the TC- 
720 circuitry and It is suggested that the controller is placed in an area of adequate ventilation for 
cooling if frequent over-current loads are expected.
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Peltier module matching
The dial-a-temp uses the Peltier effect to move heat forwards or backwards depending on input polarity. 
Differences in Peltier modules (or pads) exist in terms of temperature and other operation conditions; 
potted modules can be used for increased reliability at the expense of slightly less efficient heat transfer, 
something beneficial when working with animals. Differences in module specifications such as voltage 
and current draw need to be considered when designing a system. Input voltage should always be about 
half of the total voltage rating the manufacturer specifies for a given Peltier module and usually provides 
for the best COP (coefficient of performance), where the amount of heat removed per ampere is at 
maximum. When input voltage approaches the upper limit of the module rating, increased waste heat is 
generated and may be useful in applications requiring more heating than cooling. We are trying to both 
cool and heat the cage surface, so a 12V power source was chosen to run both the TC-720 and an array 
of modules rated to 24V (VT-199-1.4-0.8, potted; TE technology, Traverse City, MI). The maximum COP 
for these modules is obtained in the 12V range as indicated in literature from TE Technology.
Power converter
There are not many restrictions on the type of 120V AC to 12V DC power transformer as long as 
adequate current capacity is met. There is variability in current draw depending on the type of Peltier 
module chosen so a larger power converter is never a bad idea. I chose to go with a 1200W power 
supply for a PC as they are common, fairly cheap, and have relatively high conversion efficiency. The 
main limitation to total system power is the main PCB (printed circuit board) utilized in the TC-720 can 
only operate up to a 20 amp steady state current.
Plumbing
The system uses two segregated water (or coolant) circuits plumbed with 3/4" silicone heater hose and 
secured using standard worm drive clamps according to figure 1B. Coolant reservoirs in the diagram are
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constructed out of 2" schedule 40 ABS Drain waste vent pipe commonly available at hardware stores 
with end caps. The height of the reservoirs is not critical as long as the liquid level is above the cage 
surface. End caps for the bottom of these reservoirs are solvent welded, then drilled and tapped for 3/4" 
NPT (3/4" pipe thread) and sealed using liquid based Teflon sealant. A male-male 3/4" NPT fitting was 
placed in the reservoir and used to connect to a 3/4" NPT bulkhead fitting that was placed in the 
refrigerator casing prior as a method of pass-through plumbing. Each water circuit receives its own 
reservoir in-order to prevent mixing of liquid. Small automotive 12V DC pumps work well in this 
application due to small size, and low noise; brushless DC water pumps (Varimax PWM coolant pump; 
TechAFX Inc, Bloomfield, MI) were chosen after utilizing brushed type pumps which failed after about a 
year of use. Wiring and further specifications and instructions on wiring can be obtained from TechAFX.
In summary, The cage-side water circuit is plumbed to:
A) Cage bottom
B) One side of the aluminum heat transfer block
C) Water pump
D) Water (or coolant) reservoir
The waste energy water circuit is plumbed to:
A) A small radiator (A new vehicle heater core with dimensions of roughly 10"x10"x1-2" works great)
B) The other side of the aluminum heat transfer block
C) Water pump
D) Water (or coolant) reservoir.
Small in-line Schrader valves can be placed in-line with the water circuits at the top of locations that may 
accumulate water bubbles. The system must be free of trapped air, something critical if coolant is to be
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used for cooler temperatures as foaming will occur; a water-only system will not foam as much but it 
does reduce system efficiency.
Tuning the system
The TC-720 operates using PWM modulation and uses PID control (Proportional, Integral, Derivative) to 
regulate the output to the peltier modules. Tuning this type of system requires trial and error time and 
each system will be unique; if a setup is designed around my design, settings should be similar: 
Proportional= 0.75; Integral = 10; Derivative = 4. The settings will change depending on temperature 
differential between the peltier modules and ambient temperature that the radiator is located in. A 
relatively stable ambient temperature is very important or the PID control will attempt to hone in on the 
target temperature but will oscillate around it. It's easiest to change these settings after installing TC- 
720 control software on a PC in addition to serving as a datalogging device for the primary temperature 
sensor used for cage control and the secondary sensor. Further guidance for using this software can be 
obtained through TE Technology, Inc.
Further reference materials for the dial-a-temp control unit configuration may be found after figure B1 
with photos being taken during construction. The cage floor and heat transfer blocks were welded 
beforehand and pictures were not taken but construction can be inferred from the above text and 
configuration pictures below.
Methods for obtaining baseline metabolic rate in rats
All animal procedures were approved by the IACUC at the University of Alaska Fairbanks. Eight naive 
Sprague-Dawley rats (UAF colony, derived from rats obtained from Simonson Laboratories, Gilroy, CA) 
were placed into the dial-a-temp metabolic chamber to obtain baseline metabolic rate in rats vs. surface 
temperature. The device was programmed to start at 16°C and ramping automatically to 20°C, 24°C,
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28°C, 32°C, 34°C and 36°C with a one hour holding (soaking) time at each temperature. Open flow 
respirometry was used to measure oxygen consumption according to methods established in (Toien,
2013)
2.3 Results:
The dial-a-temp cage automatic temperature ramp and holding programming was tested and then 
implemented in-order to obtain baseline metabolic rate (figure 2.2 and 2.3). Results using the average 
minimum O2 consumption indicate that the basal metabolic rate for rats on a 32-36°C cage surface is 
approximately 0.9-0.85 mL O2 • g-1 • h-1 and rises as cage temperature decreases. This data shows that 
the dial-a-temp cage is capable of influencing body temperature by surface transfer and can be used to 
define the surface thermoneutral zone of an animal.
2.4 Discussion:
Some methods of temperature management in humans involves surface cooling achieved through 
placement of icepacks (Bernard et al., 2002) or water cooled pads with pad temperature adjusted based 
on target and core body temperature (Arctic Sun™). Here we describe a method for use in rodents that 
replicates the surface cooling approach used in humans. We found that controlling cage surface 
temperature provided rapid and effective modulation of core body temperature in animals treated with 
a drug
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Figure 2.2: Naive Sprague-dawley rats decrease oxygen consumption as surface temperature increases 
(mean, n=8)
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Cage tem perature (°C)
Figure 2.3: The thermoneutral zone was defined by the surface temperature that minimized O2 
consumption. (mean ± SEM, n=8)
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General Conclusion:
This thesis asked how to optimize body temperature control with pharmacological agents and ambient 
temperature control. Prior work using pharmacological agents fail to include ambient or surface 
temperature control as a parameter in body temperature control. This is despite the fact that clinical 
application of targeted temperature control often relies on surface temperature to control body 
temperature (Don et al., 2009). Our work shows that evaluating the performance of thermolytics needs 
to be done using both dose and ambient or surface temperature. Previous thermolytic agents examined 
may have more potential than previously thought if research protocols were refined to include a 
dynamic temperature control device such as the dial-a-temp. Therefore, it is my recommendation that 
this type of device should be used in the study of future thermolytic agents in order to minimize the use 
of animals when assessing thermolytic efficacy of pharmacological agents.
The performance of CHA as a thermolytic is promising, but more work needs to be done in-order to 
establish if the observed bradycardia is problematic. I am confident that thermolytics such as CHA will 
be delivered in emergency situations in the future, either by itself or in combination with other co­
treatments in-order to maximize therapeutic benefit. I am also confident that this approach will be 
extremely useful in translating aspects of thermoregulation and metabolism to humans in-order to 
minimize the risks associated with long-term spaceflight. In conclusion, reproducibility is the key when 
transferring methods from lab to lab in the pursuit of scientific advancement so it is my pleasure in 
providing the scientific community the dial-a-temp approach.
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